Literature DB >> 16507883

Pathophysiology and therapeutic potential of purinergic signaling.

Geoffrey Burnstock1.   

Abstract

The concept of a purinergic signaling system, using purine nucleotides and nucleosides as extracellular messengers, was first proposed over 30 years ago. After a brief introduction and update of purinoceptor subtypes, this article focuses on the diverse pathophysiological roles of purines and pyrimidines as signaling molecules. These molecules mediate short-term (acute) signaling functions in neurotransmission, mechanosensory transduction, secretion and vasodilatation, and long-term (chronic) signaling functions in cell proliferation, differentiation, and death involved in development and regeneration. Plasticity of purinoceptor expression in pathological conditions is frequently observed, including an increase in the purinergic component of autonomic cotransmission. Recent advances in therapies using purinergic-related drugs in a wide range of pathological conditions will be addressed with speculation on future developments in the field.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16507883     DOI: 10.1124/pr.58.1.5

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  214 in total

Review 1.  A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases.

Authors:  Nishkantha Arulkumaran; Robert J Unwin; Frederick Wk Tam
Journal:  Expert Opin Investig Drugs       Date:  2011-04-21       Impact factor: 6.206

2.  Preface to special issue (Commercial Developments in Purinergic Signalling).

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2012-02       Impact factor: 3.765

Review 3.  Perspectives of purinergic signaling in stem cell differentiation and tissue regeneration.

Authors:  Talita Glaser; Angélica Regina Cappellari; Micheli Mainardi Pillat; Isabele Cristiana Iser; Márcia Rosângela Wink; Ana Maria Oliveira Battastini; Henning Ulrich
Journal:  Purinergic Signal       Date:  2011-12-06       Impact factor: 3.765

4.  ATP release and autocrine signaling through P2X4 receptors regulate γδ T cell activation.

Authors:  Monali Manohar; Mark I Hirsh; Yu Chen; Tobias Woehrle; Anjali A Karande; Wolfgang G Junger
Journal:  J Leukoc Biol       Date:  2012-06-29       Impact factor: 4.962

Review 5.  Purinergic signaling: a novel mechanism in immune surveillance.

Authors:  Lin Mei; Wei Du; Wei Gao; Qi-bing Mei
Journal:  Acta Pharmacol Sin       Date:  2010-08-16       Impact factor: 6.150

6.  Purine receptor-mediated endocannabinoid production and retrograde synaptic signalling in the cerebellar cortex.

Authors:  Flora E Kovacs; Peter Illes; Bela Szabo
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

7.  Puerarin alleviates burn-related procedural pain mediated by P2X(3) receptors.

Authors:  Xin Li; Jun Zhang; Yun Gao; Yang Yang; Changshui Xu; Guilin Li; Guanghua Guo; Shuangmei Liu; Jinyan Xie; Shangdong Liang
Journal:  Purinergic Signal       Date:  2011-07-22       Impact factor: 3.765

Review 8.  The role of P2X7 receptors in tissue fibrosis: a brief review.

Authors:  Daniela Gentile; Mariarita Natale; Pietro Enea Lazzerini; Pier Leopoldo Capecchi; Franco Laghi-Pasini
Journal:  Purinergic Signal       Date:  2015-08-29       Impact factor: 3.765

9.  Characterisation of the R276A gain-of-function mutation in the ectodomain of murine P2X7.

Authors:  Sahil Adriouch; Felix Scheuplein; Robert Bähring; Michel Seman; Olivier Boyer; Friedrich Koch-Nolte; Friedrich Haag
Journal:  Purinergic Signal       Date:  2009-02-21       Impact factor: 3.765

Review 10.  Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states.

Authors:  D L Donnelly-Roberts; M F Jarvis
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.